EUVIMEDEUVIMED entdecken
Crossref

Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage

Yohann Loriot, Karim Fizazi

European Urology Focus · 2024-07 · 10 (4) · 511-513

DOI: 10.1016/j.euf.2024.09.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2024-07. Verfasst von Yohann Loriot und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The level of evidence for the management of prostate cancer progressing after triplet therapy is currently low. Molecular profiling of patients and enrolment in clinical trials are strongly recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHumansMaleAntineoplastic Combined Chemotherapy ProtocolsNeoplasm MetastasisProstatic NeoplasmsNeoplasm StagingAndrogen Antagonists

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.
  • Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Zitieren

APA

Loriot, Y., & Fizazi, K. (2024). Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage. European Urology Focus, 10(4), 511-513. https://doi.org/10.1016/j.euf.2024.09.017

Vancouver

Loriot Y, Fizazi K. Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage. European Urology Focus. 2024;10(4):511-513. doi:10.1016/j.euf.2024.09.017

BibTeX
@article{Loriot2024,
  author = {Loriot, Yohann and Fizazi, Karim},
  title = {Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage},
  journal = {European Urology Focus},
  year = {2024},
  volume = {10},
  number = {4},
  pages = {511--513},
  doi = {10.1016/j.euf.2024.09.017}
}
Kostenlos starten →